Brain-Computer Interface Company Synchron Secures $200M Funding
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, announced it has raised $200 million in a Series D funding round. This investment aims to fast-track commercialization of its first-generation Stentrode BCI platform and support development of the next-generation interface.
Details of the Financing Round
- The $200 million Series D round increases Synchron’s total funding to $345 million.
- Double Point Ventures led the round alongside existing investors including ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New investors in this round include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
About the Stentrode BCI Platform
Synchron’s Stentrode is the first endovascular brain-computer interface, enabling translation of brain activity into digital commands without the need for open-brain surgery. The device is implanted through a minimally invasive catheter procedure and interfaces with the motor cortex via blood vessels.
“The Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices.”
Key Innovations
- Non-surgical catheter implantation reduces risks typically associated with brain surgery.
- Wireless transmission of neural signals allows for hands-free device control.
- Supports advancement toward a next-generation brain-computer interface platform.
Author’s Summary: Synchron’s $200 million funding boosts commercialization of its pioneering Stentrode BCI, offering a non-surgical, wireless interface to translate brain signals into digital commands.